| Type: | combo |
| Width: | 235 |
| Width2: | 215 |
| Component1: | Segesterone acetate |
| Class1: | Progestogen |
| Component2: | Ethinylestradiol |
| Class2: | Estrogen |
| Tradename: | Annovera |
| Dailymedid: | Segesterone_acetate_and_ethinyl_estradiol |
| Pregnancy Us: | N |
| Routes Of Administration: | Intravaginal |
| Atc Prefix: | None |
| Legal Us: | Rx-only |
| Kegg: | D11654 |
| Synonyms: | EE/SGA; EE/SA |
Segesterone acetate/ethinylestradiol (EE/SGA), sold under the brand name Annovera, is a contraceptive vaginal ring and combined form of hormonal birth control which contains segesterone acetate, a progestin and ethinylestradiol, an estrogen.[1] [2] It contains 17.4 mg ethinylestradiol and 103 mg segesterone acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg segesterone acetate per day.[3]
Annovera is inserted into the vagina and left for 21 days, then removed, washed and stored for seven days, during which the user experiences a period (withdrawal bleeding.) This can be repeated thirteen times, for one full year of use.[4] Unlike NuvaRing, another vaginal ring contraceptive, Annovera does not need to be refrigerated before being dispensed and can be stored at temperatures up to 30 degrees Celsius.[5]
The medication was developed by the Population Council, an international non-profit organization, and licensed to TherapeuticsMD. It was approved for medical use in the United States in August 2018.[6]